Policy: MBP 112.0
Section: Medical Benefit Pharmaceutical Policy
Subject: Simponi Aria (golimumab)

I. Policy:
Simponi Aria (golimumab)

II. Purpose/Objective:
To provide a policy of coverage regarding Simponi Aria (golimumab)

III. Responsibility:
A. Medical Directors
B. Medical Management
C. Pharmacy Department

IV. Required Definitions
1. Attachment – a supporting document that is developed and maintained by the policy writer or department requiring/authoring the policy.
2. Exhibit – a supporting document developed and maintained in a department other than the department requiring/authoring the policy.
3. Devised – the date the policy was implemented.
4. Revised – the date of every revision to the policy, including typographical and grammatical changes.
5. Reviewed – the date documenting the annual review if the policy has no revisions necessary.

V. Additional Definitions
Medical Necessity or Medically Necessary means Covered Services rendered by a Health Care Provider that the Plan determines are:

a. appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury;
b. provided for the diagnosis and the direct care and treatment of the Member's condition, illness disease or injury;
c. in accordance with current standards good medical treatment practiced by the general medical community;
d. not primarily for the convenience of the Member, or the Member's Health Care Provider; and
e. the most appropriate source or level of service that can safely be provided to the Member. When applied to hospitalization, this further means that the Member requires acute care as an inpatient due to the nature of the services rendered or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient.

Medicaid Business Segment
Medical Necessity shall mean a service or benefit that is compensable under the Medical Assistance Program and if it meets any one of the following standards:

(i) the service or benefit will, or is reasonably expected to, prevent the onset of an illness, condition or disability.
(ii) the service or benefit will, or is reasonably expected to, reduce or ameliorate the physical, mental or development effects of an illness, condition, injury or disability.
(iii) the service or benefit will assist the Member to achieve or maintain maximum functional capacity in performing daily activities, taking into account both the functional capacity of the Member and those functional capacities that are appropriate for members of the same age.
DESCRIPTION:
Simponi Aria (golimumab) is a tumor necrosis factor (TNF) blocker indicated for the treatment of adult patients with moderately to severely active Rheumatoid Arthritis in combination with methotrexate.

CRITERIA FOR USE: Requires Prior Authorization by Medical Director or Designee

GRANDFATHER PROVISION – Members already established on therapy are eligible for approval as long as there is medical record documentation that the safety and effectiveness of use for the prescribed indication is supported by Food and Drug Administration (FDA) approval or adequate medical and scientific evidence in the medical literature

Simponi Aria (golimumab) will be considered medically necessary when all of the following criteria are met per indication:

Rheumatoid Arthritis
- Requesting provider must be a rheumatologist AND
- Medical record documentation of age ≥18 years AND
- Medical record documentation of a diagnosis of moderate to severe rheumatoid arthritis according the American College of Rheumatology Criteria for the Classification and Diagnosis of Rheumatoid Arthritis AND
- Medical record documentation that Simponi Aria will be given in combination with methotrexate AND
- Medical record documentation that Simponi Aria is not being used concurrently with a TNF blocker or other biologic agent AND
- Medical record documentation of an inadequate response to, contraindication to, or failure on 12 weeks of Humira*, Rinvoq*, OR Xeljanz*therapy.

Psoriatic Arthritis
- Requesting provider must be a rheumatologist or dermatologist AND
- Medical record documentation of age ≥18 years AND
- Medical record documentation of a diagnosis of moderately to severely active psoriatic arthritis, which must include the following:
  - Documentation of active psoriatic lesions OR documentation of a history of psoriasis AND
- Medical record documentation that Simponi Aria is not being used concurrently with a TNF blocker or other biologic agent AND
- Medical record documentation of an inadequate response to, contraindication to, or failure on 12 weeks of secukinumab (Cosentyx*) AND adalimumab (Humira*) therapy.

Ankylosing Spondylitis
- Requesting provider must be a rheumatologist AND
- Medical record documentation of age ≥18 years AND
- Medical record documentation of a diagnosis of ankylosing spondylitis AND
- Medical record documentation that Simponi Aria is not being used concurrently with a TNF blocker or other biologic agent AND
- Medical record documentation of an inadequate response to, contraindication to, or failure on 12 weeks of secukinumab (Cosentyx*) AND adalimumab (Humira*) therapy.

(*requires prior authorization)

AUTHORIZATION DURATION: Approval will be given for an initial duration of six (6) months. For continuation of coverage, medical record documentation of clinical improvement or lack of progression in the signs and symptoms of disease at six (6) months of Simponi Aria therapy is required.

After the initial six (6) month approval, subsequent approvals for coverage will be for a duration of one (1) year. Reevaluation of coverage will be every one (1) year requiring medical record documentation of continued or sustained improvement in the signs and symptoms of disease while on Simponi Aria therapy.
LINE OF BUSINESS:
Eligibility and contract specific benefit limitations and/or exclusions will apply. Coverage statements found in the line of business specific benefit document will supersede this policy.

This policy will be revised as necessary and reviewed no less than annually.

Devised: 07/18/14

Revised: 09/16/14, 12/30/14 (updated formulary alternatives criteria), 9/15/15 (removed joint counts), 3/20/18 (PsA and AS indication), 4/24/18 (per DHS, grandfather), 9/18/18 (RA form alt), 1/21/20 (RA form alt)

Reviewed: 9/14/16, 7/31/17